Yuyu Pharma (000220) - Total Assets
Based on the latest financial reports, Yuyu Pharma (000220) holds total assets worth ₩202.42 Billion KRW (≈ $137.18 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Yuyu Pharma - Total Assets Trend (2011–2024)
This chart illustrates how Yuyu Pharma's total assets have evolved over time, based on quarterly financial data. Also see Yuyu Pharma stock valuation for the company's overall valuation and market capitalisation.
Yuyu Pharma - Asset Composition Analysis
Current Asset Composition (December 2024)
Yuyu Pharma's total assets of ₩202.42 Billion consist of 49.1% current assets and 50.9% non-current assets. Review debt load of Yuyu Pharma to assess the company's total debt and financial obligations.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 20.1% |
| Accounts Receivable | ₩17.66 Billion | 8.5% |
| Inventory | ₩38.63 Billion | 18.6% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩2.98 Billion | 1.4% |
| Goodwill | ₩153.77 Million | 0.1% |
Asset Composition Trend (2011–2024)
This chart illustrates how Yuyu Pharma's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See current stock price of Yuyu Pharma for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Yuyu Pharma's current assets represent 49.1% of total assets in 2024, an increase from 0.0% in 2011.
- Cash Position: Cash and equivalents constituted 20.1% of total assets in 2024, up from 3.7% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 2.0% in 2011.
- Asset Diversification: The largest asset category is inventory at 18.6% of total assets.
Yuyu Pharma Competitors by Total Assets
Key competitors of Yuyu Pharma based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Kamada
TA:KMDA
|
Israel | ILA377.21 Million |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Viatris Inc
NASDAQ:VTRS
|
USA | $35.04 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥10.21 Billion |
|
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723
|
China | CN¥4.49 Billion |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
USA | $199.45 Million |
Yuyu Pharma - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.77 | 1.70 | 3.50 |
| Quick Ratio | 0.96 | 1.03 | 2.22 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩41.91 Billion | ₩43.75 Billion | ₩46.07 Billion |
Yuyu Pharma - Advanced Valuation Insights
This section examines the relationship between Yuyu Pharma's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.58 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 4.8% |
| Total Assets | ₩207.69 Billion |
| Market Capitalization | $42.22 Million USD |
Valuation Analysis
Below Book Valuation: The market values Yuyu Pharma's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Yuyu Pharma's assets grew by 4.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Yuyu Pharma (2011–2024)
The table below shows the annual total assets of Yuyu Pharma from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩207.69 Billion ≈ $140.75 Million |
+4.78% |
| 2023-12-31 | ₩198.21 Billion ≈ $134.33 Million |
+1.54% |
| 2022-12-31 | ₩195.21 Billion ≈ $132.29 Million |
+1.15% |
| 2021-12-31 | ₩192.99 Billion ≈ $130.78 Million |
+24.59% |
| 2020-12-31 | ₩154.90 Billion ≈ $104.97 Million |
+12.48% |
| 2019-12-31 | ₩137.72 Billion ≈ $93.33 Million |
+1.84% |
| 2018-12-31 | ₩135.23 Billion ≈ $91.64 Million |
+11.31% |
| 2017-12-31 | ₩121.49 Billion ≈ $82.33 Million |
+9.16% |
| 2016-12-31 | ₩111.30 Billion ≈ $75.43 Million |
+6.68% |
| 2015-12-31 | ₩104.33 Billion ≈ $70.70 Million |
+2.89% |
| 2014-12-31 | ₩101.40 Billion ≈ $68.72 Million |
+5.34% |
| 2013-12-31 | ₩96.26 Billion ≈ $65.24 Million |
+8.55% |
| 2012-12-31 | ₩88.68 Billion ≈ $60.10 Million |
+0.20% |
| 2011-12-31 | ₩88.51 Billion ≈ $59.98 Million |
-- |
About Yuyu Pharma
Yuyu Pharma, Inc. develops and markets pharmaceutical products in Korea and United States. The company offers various prescription drugs, non-prescription drugs, quasi-drugs, health functional foods, and other products in the fields of neurology, endocrinology, otolaryngology, etc. The company was formerly known as YuYu Inc. and changed its name to Yuyu Pharma, Inc. in May 2008. Yuyu Pharma, Inc.… Read more